Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC’s ‘Final Trades’

Benzinga – by Avi Kapoor, Benzinga Staff Writer. On CNBC’s “Halftime Report Final Trades,” Joshua Brown of Ritholtz Wealth Management said under £30, Pfizer Inc. (NYSE:PFE) is a gift. Pfizer is looking to build on the success of its COVID-19 vaccine rollout by introducing a direct-to-consumer medicines platform under the brand “Pfizer for All.”

Jim Lebenthal of Cerity Partners said QUALCOMM Incorporated (NASDAQ:QCOM) is breaking out right now. On May 14, Qualcomm and Aramco reported a collaboration that includes accelerating development of industrial 4G/5G NGN ecosystem. Don’t forget to check out our premarket coverage here

Sarat Sethi of DCLA said Freeport-McMoRan Inc. (NYSE:FCX) is a copper play, and demand for copper is going through the roof. On April 23, Freeport said first-quarter revenue stood at £6.32 billion, beating the consensus of £5.66 billion. Adjusted EPS was 32 cents, beating the consensus of 27 cents.

Amy Raskin of Chevy Chase Trust named Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) as her final trade. On May 6, Vertex Pharmaceuticals posted stronger-than-expected results for its first quarter. Price Action:

Pfizer shares fell 0.2% to close at £28.38 on Tuesday.
Qualcomm gained 2.6% to settle at £188.97 during Tuesday’s session.
Freeport-McMoRan shares rose 2.8% to settle at £53.48 on Tuesday.
Vertex Pharmaceuticals shares slipped 0.3% to close at £428.59 on Tuesday.

Image: Shutterstock

Read the original article on Benzinga [1]

References

^ Read the original article on Benzinga (www.benzinga.com)